26 related articles for article (PubMed ID: 1812892)
1. Hormones and B-cell development in health and autoimmunity.
Santana-Sánchez P; Vaquero-García R; Legorreta-Haquet MV; Chávez-Sánchez L; Chávez-Rueda AK
Front Immunol; 2024; 15():1385501. PubMed ID: 38680484
[TBL] [Abstract][Full Text] [Related]
2. Safety of hormonal replacement therapy and oral contraceptives in systemic lupus erythematosus: a systematic review and meta-analysis.
Rojas-Villarraga A; Torres-Gonzalez JV; Ruiz-Sternberg ÁM
PLoS One; 2014; 9(8):e104303. PubMed ID: 25137236
[TBL] [Abstract][Full Text] [Related]
3. The MRL/lpr mouse strain as a model for neuropsychiatric systemic lupus erythematosus.
Gulinello M; Putterman C
J Biomed Biotechnol; 2011; 2011():207504. PubMed ID: 21331367
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-10 deficiency increases atherosclerosis, thrombosis, and low-density lipoproteins in apolipoprotein E knockout mice.
Caligiuri G; Rudling M; Ollivier V; Jacob MP; Michel JB; Hansson GK; Nicoletti A
Mol Med; 2003; 9(1-2):10-7. PubMed ID: 12765335
[TBL] [Abstract][Full Text] [Related]
5. Additive effects of suboptimal doses of estrogen and cortisone on the suppression of T lymphocyte dependent inflammatory responses in mice.
Carlsten H; Verdrengh M; Taube M
Inflamm Res; 1996 Jan; 45(1):26-30. PubMed ID: 8821775
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of a model for post-partum arthritis and the role of oestrogen in prevention of MRL-lpr associated rheumatic conditions.
Ratkay LG; Zhang D; Tonzetich J; Levy JG; Waterfield JD
Clin Exp Immunol; 1994 Oct; 98(1):52-9. PubMed ID: 7923884
[TBL] [Abstract][Full Text] [Related]
7. Pathogenesis of kidney disease in systemic lupus erythematosus.
Bagavant H; Fu SM
Curr Opin Rheumatol; 2009 Sep; 21(5):489-94. PubMed ID: 19584729
[TBL] [Abstract][Full Text] [Related]
8. The kidney in systemic lupus erythematosus.
Cameron JS; Turner DR; Vosnides G; Leibowitz S; Lessof MH; Ogg CS; Chantler C; Brown CB
Perspect Nephrol Hypertens; 1977; 6():41-81. PubMed ID: 320552
[No Abstract] [Full Text] [Related]
9. Histocompatibility complex gene products and exposure to oestrogen: two independent disease accelerating factors in murine lupus.
Carlsten H; Tarkowski A
Scand J Immunol; 1993 Oct; 38(4):341-7. PubMed ID: 8210997
[TBL] [Abstract][Full Text] [Related]
10. Expression of heterozygous lpr gene in MRL mice. II. Acceleration of glomerulonephritis, sialadenitis, and autoantibody production.
Carlsten H; Tarkowski A; Jonsson R; Nilsson LA
Scand J Immunol; 1990 Jul; 32(1):21-8. PubMed ID: 2382106
[TBL] [Abstract][Full Text] [Related]
11. Estrogen accelerates immune complex glomerulonephritis but ameliorates T cell-mediated vasculitis and sialadenitis in autoimmune MRL lpr/lpr mice.
Carlsten H; Nilsson N; Jonsson R; Bäckman K; Holmdahl R; Tarkowski A
Cell Immunol; 1992 Oct; 144(1):190-202. PubMed ID: 1394437
[TBL] [Abstract][Full Text] [Related]
12. Differential effect of the autoimmune Yaa and lpr genes on the acceleration of lupus-like syndrome in MRL/MpJ mice.
Merino R; Shibata T; De Kossodo S; Izui S
Eur J Immunol; 1989 Nov; 19(11):2131-7. PubMed ID: 2599002
[TBL] [Abstract][Full Text] [Related]
13. Oestrogen is a potent disease accelerator in SLE-prone MRL lpr/lpr mice.
Carlsten H; Tarkowski A; Holmdahl R; Nilsson LA
Clin Exp Immunol; 1990 Jun; 80(3):467-73. PubMed ID: 2372993
[TBL] [Abstract][Full Text] [Related]
14. Differential effects of oestrogen in murine lupus: acceleration of glomerulonephritis and amelioration of T cell-mediated lesions.
Carlsten H; Nilsson N; Jonsson R; Tarkowski A
J Autoimmun; 1991 Dec; 4(6):845-56. PubMed ID: 1812892
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
